A214370 Stock Overview
A biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Caregen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩28,450.00 |
| 52 Week High | ₩28,900.00 |
| 52 Week Low | ₩14,850.00 |
| Beta | 0.16 |
| 1 Month Change | 28.15% |
| 3 Month Change | 48.64% |
| 1 Year Change | 3.45% |
| 3 Year Change | 114.56% |
| 5 Year Change | n/a |
| Change since IPO | 32.94% |
Recent News & Updates
Earnings Not Telling The Story For Caregen Co., Ltd. (KOSDAQ:214370) After Shares Rise 29%
Dec 20
Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 21Recent updates
Earnings Not Telling The Story For Caregen Co., Ltd. (KOSDAQ:214370) After Shares Rise 29%
Dec 20Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 21Why We're Not Concerned Yet About Caregen Co., Ltd.'s (KOSDAQ:214370) 26% Share Price Plunge
Aug 06Caregen (KOSDAQ:214370) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Mar 18With Caregen Co., Ltd. (KOSDAQ:214370) It Looks Like You'll Get What You Pay For
Mar 05A Look At The Fair Value Of Caregen Co., Ltd. (KOSDAQ:214370)
Apr 20Here's How We Evaluate Caregen Co., Ltd.'s (KOSDAQ:214370) Dividend
Mar 02Caregen (KOSDAQ:214370) Is Growing Earnings But Are They A Good Guide?
Feb 04
Do Its Financials Have Any Role To Play In Driving Caregen Co., Ltd.'s (KOSDAQ:214370) Stock Up Recently?
Jan 14Caregen Co., Ltd. (KOSDAQ:214370) Goes Ex-Dividend Soon
Dec 25Do Insiders Own Lots Of Shares In Caregen Co., Ltd. (KOSDAQ:214370)?
Dec 10Is Caregen Co., Ltd. (KOSDAQ:214370) A Great Dividend Stock?
Nov 19Shareholder Returns
| A214370 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 13.3% | 1.0% | -0.9% |
| 1Y | 3.5% | 2.4% | -9.0% |
Return vs Industry: A214370 matched the KR Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: A214370 exceeded the KR Market which returned -9% over the past year.
Price Volatility
| A214370 volatility | |
|---|---|
| A214370 Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A214370 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A214370's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 180 | Yongji Chung | caregen.co.kr |
Caregen Co., Ltd., a biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. The company offers filler products under the REVOFIL, DR CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names; skin care products under the Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert names; scalp care products under the Renokin and Pelo Baum names; and healthy foods under the proGsterol name.
Caregen Co., Ltd. Fundamentals Summary
| A214370 fundamental statistics | |
|---|---|
| Market cap | ₩1.39t |
| Earnings (TTM) | ₩35.79b |
| Revenue (TTM) | ₩78.67b |
38.9x
P/E Ratio17.7x
P/S RatioIs A214370 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214370 income statement (TTM) | |
|---|---|
| Revenue | ₩78.67b |
| Cost of Revenue | ₩20.41b |
| Gross Profit | ₩58.25b |
| Other Expenses | ₩22.46b |
| Earnings | ₩35.79b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 730.51 |
| Gross Margin | 74.05% |
| Net Profit Margin | 45.50% |
| Debt/Equity Ratio | 0% |
How did A214370 perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield121%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 09:17 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Caregen Co., Ltd. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Byung Hwa Han | Eugene Investment & Securities Co Ltd. |
| Brian Cho | HSBC |
| Sang-Hun Lee | iM Securities |